Corticotropin-releasing factor family and its receptors: Tumor therapeutic targets?

被引：18

作者：

Wang, Juejin ^{[1
]}

Li, Shengnan ^{[1
]}

机构：

[1] Nanjing Med Univ, Dept Pharmacol, Nanjing 210029, Peoples R China

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2007年 / 362卷 / 04期

关键词：

urocortin; corticotropin-releasing factor; corticotropin-releasing factor receptor; tumor angiogenesis; tumor chemotherapy;

D O I：

10.1016/j.bbrc.2007.08.014

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Urocortin (UCN) and corticotropin-releasing factor (CRF) are members of CRF family. Though CRF is mainly distributed in central nervous system (CNS), UCN has been reported to play biologically diverse roles in several systems such as cardiovascular, respiratory, digestive, reproductive, stress, immunologic system, etc. UCN and CRF bind to two known receptors, CRFR1 and CRFR2, to function. Both CRF receptors are distributed in CNS and periphery tissues, and their expression in cancer tissues has been reported. Now there are many documents indicating UCN/CRF play an important role in the regulation of carcinogenesis. There is also evidence indicating UCN/CRF have anticancer effects via CRFRs. This paper will review the effects of CRF family in cancers. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：785 / 788

页数：4

共 41 条

[1] Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin [J].

Arbiser, JL ;

Karalis, K ;

Viswanathan, A ;

Koike, C ;

Anand-Apte, B ;

Flynn, E ;

Zetter, B ;

Majzoub, JA .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) :838-842

[2] Expression of urocortin mRNA and peptide in the human prostate and in prostatic adenocarcinoma [J].

Arcuri, F ;

Cintorino, M ;

Florio, P ;

Floccari, F ;

Pergola, L ;

Romagnoli, R ;

Petraglia, F ;

Tosi, P ;

del Vecchio, MT .

PROSTATE, 2002, 52 (03) :167-172

[3] Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization [J].

Bale, TL ;

Giordano, FJ ;

Hickey, RP ;

Huang, Y ;

Nath, AK ;

Peterson, KL ;

Vale, WW ;

Lee, KF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (11) :7734-7739

[4] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[5] Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway [J].

Brar, BK ;

Jonassen, AK ;

Stephanou, A ;

Santilli, G ;

Railson, J ;

Knight, RA ;

Yellon, DM ;

Latchman, DS .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8508-8514

[6]

Carlson KW, 2001, ANTICANCER RES, V21, P1173

[7] Corticotropin-releasing factor (CRF) receptor type 2 in the human stomach:: Protective biological role by inhibition of apoptosis [J].

Chatzaki, Ekaterini ;

Lambropoulou, Maria ;

Constantinidis, Theodoros C. ;

Papadopoulos, Nikolaos ;

Tache, Yvette ;

Minopoulos, George ;

Grigoriadis, Dimitri E. .

JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 209 (03) :905-911

[8] Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells [J].

Fazal, N ;

Slominski, A ;

Choudhry, MA ;

Wei, ET ;

Sayeed, MM .

FEBS LETTERS, 1998, 435 (2-3) :187-190

[9] Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: Ancient CRF paralogs [J].

Fekete, Eva M. ;

Zorrilla, Eric P. .

FRONTIERS IN NEUROENDOCRINOLOGY, 2007, 28 (01) :1-27

[10] Urocortin expression is downregulated in human endometrial carcinoma [J].

Florio, Pasquale ;

De Falco, Giulia ;

Leucci, Eleonora ;

Torricelli, Michela ;

Torres, Paulo B. ;

Toti, Paolo ;

Dell'Anna, Arianna ;

Tiso, Ennio ;

Santopietro, Rosa ;

Leoncini, Lorenzo ;

Petraglia, Felice .

JOURNAL OF ENDOCRINOLOGY, 2006, 190 (01) :99-105

← 1 2 3 4 5 →